vs
Autonomix Medical, Inc.（AMIX）与HeartSciences Inc.（HSCS）财务数据对比。点击上方公司名可切换其他公司
Autonomix Medical是一家专注于心脏电生理领域的医疗科技企业，主要开发用于心律失常诊断与治疗的微创医疗设备，服务北美、欧洲地区的医疗机构与患者，致力于提升心律相关心脏疾病的诊疗效率与效果。
迈瑞尔生命科学是一家总部位于印度古吉拉特邦瓦皮的跨国医疗器械企业，隶属于比拉基亚集团，2006年成立。公司主营血管介入器械、骨科植入物、外科手术器械、耳鼻喉科产品及体外诊断试剂的研发生产，业务覆盖全球150余个国家，截至2024年共有员工1万人。
AMIX vs HSCS — 直观对比
营收规模更大
HSCS
是对方的Infinity倍
$0
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $0 | $2.4K |
| 净利润 | $-3.3M | $-2.4M |
| 毛利率 | — | 58.3% |
| 营业利润率 | — | -85713.2% |
| 净利率 | — | -97179.4% |
| 营收同比 | — | — |
| 净利润同比 | -20.2% | -12.9% |
| 每股收益（稀释后） | — | $-0.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMIXHSCS
| Q4 25 | $0 | $2.4K | ||
| Q3 25 | $0 | $1.9K | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | $0 | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | $14.7K |
净利润AMIXHSCS
| Q4 25 | $-3.3M | $-2.4M | ||
| Q3 25 | $-7.5M | $-2.1M | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $-3.2M | $-2.5M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.8M | — | ||
| Q2 24 | $-2.7M | — | ||
| Q1 24 | — | $-1.6M |
毛利率AMIXHSCS
| Q4 25 | — | 58.3% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 69.0% |
营业利润率AMIXHSCS
| Q4 25 | — | -85713.2% | ||
| Q3 25 | — | -98637.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10376.7% |
净利率AMIXHSCS
| Q4 25 | — | -97179.4% | ||
| Q3 25 | — | -108157.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11182.4% |
每股收益（稀释后）AMIXHSCS
| Q4 25 | — | $-0.85 | ||
| Q3 25 | — | $-1.58 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-2.57 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-3.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.9M | $2.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $4.2M |
| 总资产 | $10.2M | $6.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMIXHSCS
| Q4 25 | $9.9M | $2.0M | ||
| Q3 25 | $7.5M | $2.8M | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $9.1M | $2.6M | ||
| Q4 24 | $11.8M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $6.8M | — | ||
| Q1 24 | — | $7.1M |
股东权益AMIXHSCS
| Q4 25 | $8.6M | $4.2M | ||
| Q3 25 | $6.4M | $3.1M | ||
| Q2 25 | $7.0M | — | ||
| Q1 25 | $8.1M | $1.8M | ||
| Q4 24 | $9.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $5.3M | — | ||
| Q1 24 | — | $8.6M |
总资产AMIXHSCS
| Q4 25 | $10.2M | $6.0M | ||
| Q3 25 | $7.9M | $6.4M | ||
| Q2 25 | $9.0M | — | ||
| Q1 25 | $9.8M | $5.7M | ||
| Q4 24 | $12.0M | — | ||
| Q3 24 | $5.4M | — | ||
| Q2 24 | $7.1M | — | ||
| Q1 24 | — | $10.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.0M | $-2.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMIXHSCS
| Q4 25 | $-3.0M | $-2.3M | ||
| Q3 25 | $-3.8M | $-2.0M | ||
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $-2.6M | $-1.6M | ||
| Q4 24 | $-2.3M | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | — | $-2.1M |
自由现金流AMIXHSCS
| Q4 25 | $-3.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | — | $-2.1M |
自由现金流率AMIXHSCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14352.1% |
资本支出强度AMIXHSCS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 59.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
